| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Fusion Protein:PARP14-CYP2C8 |
Fusion Protein Summary |
 Fusion gene summary |
| Fusion partner gene information | Fusion gene name: PARP14-CYP2C8 | FusionPDB ID: 62814 | FusionGDB2.0 ID: 62814 | Hgene | Tgene | Gene symbol | PARP14 | CYP2C8 | Gene ID | 54625 | 1558 |
| Gene name | poly(ADP-ribose) polymerase family member 14 | cytochrome P450 family 2 subfamily C member 8 | |
| Synonyms | ARTD8|BAL2|PARP-14|pART8 | CPC8|CYP2C8DM|CYPIIC8|MP-12/MP-20 | |
| Cytomap | 3q21.1 | 10q23.33 | |
| Type of gene | protein-coding | protein-coding | |
| Description | protein mono-ADP-ribosyltransferase PARP14ADP-ribosyltransferase diphtheria toxin-like 8B-aggressive lymphoma 2b aggressive lymphoma protein 2collaborator of STAT6poly [ADP-ribose] polymerase 14 | cytochrome P450 2C8P450 form 1cytochrome P450 IIC2cytochrome P450 MP-12cytochrome P450 MP-20cytochrome P450 form 1cytochrome P450, family 2, subfamily C, polypeptide 8cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8flavopr | |
| Modification date | 20200313 | 20200320 | |
| UniProtAcc | . | P10632 | |
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000475640, ENST00000474629, | ENST00000371270, ENST00000539050, ENST00000535898, |
| Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 8 X 7 X 5=280 | 6 X 2 X 5=60 |
| # samples | 9 | 6 | |
| ** MAII score | log2(9/280*10)=-1.63742992061529 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/60*10)=0 | |
| Context (manual curation of fusion genes in FusionPDB) | PubMed: PARP14 [Title/Abstract] AND CYP2C8 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | PARP14(122439235)-CYP2C8(96827448), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | PARP14-CYP2C8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PARP14-CYP2C8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. PARP14-CYP2C8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. PARP14-CYP2C8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PARP14 | GO:0006471 | protein ADP-ribosylation | 27796300 |
| Tgene | CYP2C8 | GO:0002933 | lipid hydroxylation | 14559847 |
| Tgene | CYP2C8 | GO:0006082 | organic acid metabolic process | 19651758 |
| Tgene | CYP2C8 | GO:0008202 | steroid metabolic process | 14559847 |
| Tgene | CYP2C8 | GO:0008210 | estrogen metabolic process | 12865317|14559847 |
| Tgene | CYP2C8 | GO:0017144 | drug metabolic process | 19651758 |
| Tgene | CYP2C8 | GO:0019373 | epoxygenase P450 pathway | 7574697 |
| Tgene | CYP2C8 | GO:0042573 | retinoic acid metabolic process | 11093772 |
| Tgene | CYP2C8 | GO:0042738 | exogenous drug catabolic process | 18619574 |
| Tgene | CYP2C8 | GO:0046456 | icosanoid biosynthetic process | 15766564 |
| Tgene | CYP2C8 | GO:0055114 | oxidation-reduction process | 19651758 |
| Tgene | CYP2C8 | GO:0070989 | oxidative demethylation | 18619574 |
| Fusion gene breakpoints across PARP14 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across CYP2C8 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Fusion Gene Sample Information |
| Fusion gene information from FusionGDB2.0. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | Non-Cancer | TCGA-DD-A1EH-11A | PARP14 | chr3 | 122439235 | + | CYP2C8 | chr10 | 96827448 | - |
Top |
Fusion ORF Analysis |
| Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000474629 | PARP14 | chr3 | 122439235 | + | ENST00000371270 | CYP2C8 | chr10 | 96827448 | - | 6867 | 5207 | 260 | 6511 | 2083 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000474629 | ENST00000371270 | PARP14 | chr3 | 122439235 | + | CYP2C8 | chr10 | 96827448 | - | 0.000223675 | 0.9997763 |
Top |
Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP >62814_62814_1_PARP14-CYP2C8_PARP14_chr3_122439235_ENST00000474629_CYP2C8_chr10_96827448_ENST00000371270_length(amino acids)=2083AA_BP=1649 MRMAVPGSFPLLVEGSWGPDPPKNLNTKLQMYFQSPKRSGGGECEVRQDPRSPSRFLVFFYPEDVRQKVLERKNHELVWQGKGTFKLTVQ LPATPDEIDHVFEEELLTKESKTKEDVKEPDVSEELDTKLPLDGGLDKMEDIPEECENISSLVAFENLKANVTDIMLILLVENISGLSND DFQVEIIRDFDVAVVTFQKHIDTIRFVDDCTKHHSIKQLQLSPRLLEVTNTIRVENLPPGADDYSLKLFFENPYNGGGRVANVEYFPEES SALIEFFDRKVLDTIMATKLDFNKMPLSVFPYYASLGTALYGKEKPLIKLPAPFEESLDLPLWKFLQKKNHLIEEINDEMRRCHCELTWS QLSGKVTIRPAATLVNEGRPRIKTWQADTSTTLSSIRSKYKVNPIKVDPTMWDTIKNDVKDDRILIEFDTLKEMVILAGKSEDVQSIEVQ VRELIESTTQKIKREEQSLKEKMIISPGRYFLLCHSSLLDHLLTECPEIEICYDRVTQHLCLKGPSADVYKAKCEIQEKVYTMAQKNIQV SPEIFQFLQQVNWKEFSKCLFIAQKILALYELEGTTVLLTSCSSEALLEAEKQMLSALNYKRIEVENKEVLHGKKWKGLTHNLLKKQNSS PNTVIINELTSETTAEVIITGCVKEVNETYKLLFNFVEQNMKIERLVEVKPSLVIDYLKTEKKLFWPKIKKVNVQVSFNPENKQKGILLT GSKTEVLKAVDIVKQVWDSVCVKSVHTDKPGAKQFFQDKARFYQSEIKRLFGCYIELQENEVMKEGGSPAGQKCFSRTVLAPGVVLIVQQ GDLARLPVDVVVNASNEDLKHYGGLAAALSKAAGPELQADCDQIVKREGRLLPGNATISKAGKLPYHHVIHAVGPRWSGYEAPRCVYLLR RAVQLSLCLAEKYKYRSIAIPAISSGVFGFPLGRCVETIVSAIKENFQFKKDGHCLKEIYLVDVSEKTVEAFAEAVKTVFKATLPDTAAP PGLPPAAAGPGKTSWEKGSLVSPGGLQMLLVKEGVQNAKTDVVVNSVPLDLVLSRGPLSKSLLEKAGPELQEELDTVGQGVAVSMGTVLK TSSWNLDCRYVLHVVAPEWRNGSTSSLKIMEDIIRECMEITESLSLKSIAFPAIGTGNLGFPKNIFAELIISEVFKFSSKNQLKTLQEVH FLLHPSDHENIQAFSDEFARRANGNLVSDKIPKAKDTQGFYGTVSSPDSGVYEMKIGSIIFQVASGDITKEEADVIVNSTSNSFNLKAGV SKAILECAGQNVERECSQQAQQRKNDYIITGGGFLRCKNIIHVIGGNDVKSSVSSVLQECEKKNYSSICLPAIGTGNAKQHPDKVAEAII DAIEDFVQKGSAQSVKKVKVVIFLPQVLDVFYANMKKREGTQLSSQQSVMSKLASFLGFSKQSPQKKNHLVLEKKTESATFRVCGENVTC VEYAISWLQDLIEKEQCPYTSEDECIKDFDEKEYQELNELQKKLNINISLDHKRPLIKVLGISRDVMQARDEIEAMIKRVRLAKEQESRA DCISEFIEWQYNDNNTSHCFNKMTNLKLEDARREKKKTVDVKINHRHYTVNLNTYTATDTKGHSLSVQRLTKSKVDIPAHWSDMKQQNFC VVELLPSDPEYNTVASKFNQTCSHFRIEKFSKVYGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNG KRWKEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICSVVFQKRFDYKDQNFLTLMKRFNENFRI LNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALTRSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVA GTETTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSDLVPTGVPHAVTTDTKFRNYLIPKGTTI MALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFKKSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIV -------------------------------------------------------------- |
Top |
Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:122439235/chr10:96827448) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | CYP2C8 |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:7574697, PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:7574697, PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond (PubMed:7574697, PubMed:15766564, PubMed:19965576). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form (PubMed:11093772). Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) (PubMed:14559847). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) (PubMed:26427316). {ECO:0000269|PubMed:11093772, ECO:0000269|PubMed:14559847, ECO:0000269|PubMed:15766564, ECO:0000269|PubMed:19965576, ECO:0000269|PubMed:26427316, ECO:0000269|PubMed:7574697}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1003_1190 | 1647.0 | 1802.0 | Domain | Macro 2 |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1216_1387 | 1647.0 | 1802.0 | Domain | Macro 3 |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1523_1601 | 1647.0 | 1802.0 | Domain | WWE |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 791_978 | 1647.0 | 1802.0 | Domain | Macro 1 |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1023_1024 | 1647.0 | 1802.0 | Region | Substrate 2 binding |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1046_1049 | 1647.0 | 1802.0 | Region | Substrate 2 binding |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1133_1137 | 1647.0 | 1802.0 | Region | Substrate 2 binding |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1175_1178 | 1647.0 | 1802.0 | Region | Substrate 2 binding |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1235_1236 | 1647.0 | 1802.0 | Region | Substrate 3 binding |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1332_1336 | 1647.0 | 1802.0 | Region | Substrate 3 binding |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 922_926 | 1647.0 | 1802.0 | Region | Substrate 1 binding |
| - Not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | PARP14 | chr3:122439235 | chr10:96827448 | ENST00000474629 | + | 15 | 17 | 1605_1801 | 1647.0 | 1802.0 | Domain | PARP catalytic |
Top |
Fusion Protein-Protein Interaction |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type from validated records (BIOGRID-3.4.160) |
| Gene | PPI interactors |
| Protein-protein interactors based on sequence similarity (STRING) |
| Gene | STRING network |
| PARP14 | |
| CYP2C8 |
| - Retained interactions in fusion protein (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost interactions due to fusion (protein functional feature from UniProt). |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs to PARP14-CYP2C8 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to PARP14-CYP2C8 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies